{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T05:07:03Z","timestamp":1790744823452,"version":"4.1.0"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2021,5,6]],"date-time":"2021-05-06T00:00:00Z","timestamp":1620259200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,5,6]],"date-time":"2021-05-06T00:00:00Z","timestamp":1620259200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Res Cardiol"],"published-print":{"date-parts":[[2021,8]]},"DOI":"10.1007\/s00392-021-01851-w","type":"journal-article","created":{"date-parts":[[2021,5,6]],"date-time":"2021-05-06T06:03:00Z","timestamp":1620280980000},"page":"1308-1320","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Diuretic therapy as prognostic enrichment factor for clinical trials in patients with heart failure with reduced ejection fraction"],"prefix":"10.1007","volume":"110","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9463-5055","authenticated-orcid":false,"given":"Stefano","family":"Coiro","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Girerd","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John J. V.","family":"McMurray","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bertram","family":"Pitt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karl","family":"Swedberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dirk J.","family":"van Veldhuisen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zohra","family":"Lamiral","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Rossignol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Faiez","family":"Zannad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,5,6]]},"reference":[{"key":"1851_CR1","unstructured":"(FDA). FaDA (2019) Enrichment strategies for clinical trials to support determination of effectiveness of human drugs and biological products guidance for industry [Internet]. Silver Spring, MD: FDA. https:\/\/www.fda.gov\/media\/121320\/download"},{"issue":"4","key":"1851_CR2","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1161\/circheartfailure.113.001281","volume":"7","author":"NA Bello","year":"2014","unstructured":"Bello NA, Claggett B, Desai AS, McMurray JJ, Granger CB, Yusuf S, Swedberg K, Pfeffer MA, Solomon SD (2014) Influence of previous heart failure hospitalization on cardiovascular events in patients with reduced and preserved ejection fraction. Circ Heart Fail 7(4):590\u2013595. https:\/\/doi.org\/10.1161\/circheartfailure.113.001281","journal-title":"Circ Heart Fail"},{"issue":"13","key":"1851_CR3","doi-asserted-by":"publisher","first-page":"1482","DOI":"10.1161\/circulationaha.107.696906","volume":"116","author":"SD Solomon","year":"2007","unstructured":"Solomon SD, Dobson J, Pocock S, Skali H, McMurray JJ, Granger CB, Yusuf S, Swedberg K, Young JB, Michelson EL, Pfeffer MA (2007) Influence of nonfatal hospitalization for heart failure on subsequent mortality in patients with chronic heart failure. Circulation 116(13):1482\u20131487. https:\/\/doi.org\/10.1161\/circulationaha.107.696906","journal-title":"Circulation"},{"key":"1851_CR4","doi-asserted-by":"publisher","DOI":"10.1016\/j.jchf.2019.12.010","author":"NE Ibrahim","year":"2020","unstructured":"Ibrahim NE, Burnett JC Jr, Butler J, Camacho A, Felker GM, Fiuzat M, O\u2019Connor C, Solomon SD, Vaduganathan M, Zile MR, Januzzi JL Jr (2020) Natriuretic peptides as inclusion criteria in clinical trials: a JACC heart failure position paper. JACC Heart Fail. https:\/\/doi.org\/10.1016\/j.jchf.2019.12.010","journal-title":"JACC Heart Fail"},{"issue":"13","key":"1851_CR5","doi-asserted-by":"publisher","first-page":"1780","DOI":"10.1161\/01.Cir.0000143059.68996.A7","volume":"110","author":"F Hartmann","year":"2004","unstructured":"Hartmann F, Packer M, Coats AJ, Fowler MB, Krum H, Mohacsi P, Rouleau JL, Tendera M, Castaigne A, Anker SD, Amann-Zalan I, Hoersch S, Katus HA (2004) Prognostic impact of plasma N-terminal pro-brain natriuretic peptide in severe chronic congestive heart failure: a substudy of the carvedilol prospective randomized cumulative survival (COPERNICUS) trial. Circulation 110(13):1780\u20131786. https:\/\/doi.org\/10.1161\/01.Cir.0000143059.68996.A7","journal-title":"Circulation"},{"issue":"5","key":"1851_CR6","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1161\/circheartfailure.111.962654","volume":"4","author":"IS Anand","year":"2011","unstructured":"Anand IS, Rector TS, Cleland JG, Kuskowski M, McKelvie RS, Persson H, McMurray JJ, Zile MR, Komajda M, Massie BM, Carson PE (2011) Prognostic value of baseline plasma amino-terminal pro-brain natriuretic peptide and its interactions with irbesartan treatment effects in patients with heart failure and preserved ejection fraction: findings from the I-PRESERVE trial. Circ Heart Fail 4(5):569\u2013577. https:\/\/doi.org\/10.1161\/circheartfailure.111.962654","journal-title":"Circ Heart Fail"},{"issue":"3","key":"1851_CR7","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1016\/j.jchf.2017.12.014","volume":"6","author":"G Savarese","year":"2018","unstructured":"Savarese G, Orsini N, Hage C, Vedin O, Cosentino F, Rosano GMC, Dahlstr\u00f6m U, Lund LH (2018) Utilizing NT-proBNP for eligibility and enrichment in trials in HFpEF, HFmrEF, and HFrEF. JACC Heart Fail 6(3):246\u2013256. https:\/\/doi.org\/10.1016\/j.jchf.2017.12.014","journal-title":"JACC Heart Fail"},{"key":"1851_CR8","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD003838.pub3","author":"RF Faris","year":"2012","unstructured":"Faris RF, Flather M, Purcell H, Poole-Wilson PA, Coats AJS (2012) Diuretics for heart failure. Cochrane Database Syst Rev. https:\/\/doi.org\/10.1002\/14651858.CD003838.pub3","journal-title":"Cochrane Database Syst Rev"},{"issue":"16","key":"1851_CR9","doi-asserted-by":"publisher","first-page":"e240","DOI":"10.1161\/CIR.0b013e31829e8776","volume":"128","author":"CW Yancy","year":"2013","unstructured":"Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE, Drazner MH, Fonarow GC, Geraci SA, Horwich T, Januzzi JL, Johnson MR, Kasper EK, Levy WC, Masoudi FA, McBride PE, McMurray JJV, Mitchell JE, Peterson PN, Riegel B, Sam F, Stevenson LW, Tang WHW, Tsai EJ, Wilkoff BL (2013) 2013 ACCF\/AHA guideline for the management of heart failure. Circulation 128(16):e240\u2013e327. https:\/\/doi.org\/10.1161\/CIR.0b013e31829e8776","journal-title":"Circulation"},{"issue":"8","key":"1851_CR10","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1002\/ejhf.592","volume":"18","author":"P Ponikowski","year":"2016","unstructured":"Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JG, Coats AJ, Falk V, Gonzalez-Juanatey JR, Harjola VP, Jankowska EA, Jessup M, Linde C, Nihoyannopoulos P, Parissis JT, Pieske B, Riley JP, Rosano GM, Ruilope LM, Ruschitzka F, Rutten FH, van der Meer P (2016) ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail 18(8):891\u2013975. https:\/\/doi.org\/10.1002\/ejhf.592","journal-title":"Eur J Heart Fail"},{"issue":"12","key":"1851_CR11","doi-asserted-by":"publisher","first-page":"1759","DOI":"10.1016\/j.amjcard.2005.12.072","volume":"97","author":"S Eshaghian","year":"2006","unstructured":"Eshaghian S, Horwich TB, Fonarow GC (2006) Relation of loop diuretic dose to mortality in advanced heart failure. Am J Cardiol 97(12):1759\u20131764. https:\/\/doi.org\/10.1016\/j.amjcard.2005.12.072","journal-title":"Am J Cardiol"},{"issue":"2","key":"1851_CR12","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1177\/1074248410388807","volume":"16","author":"J Martins","year":"2011","unstructured":"Martins J, Lourenco P, Araujo JP, Mascarenhas J, Lopes R, Azevedo A, Bettencourt P (2011) Prognostic implications of diuretic dose in chronic heart failure. J Cardiovasc Pharmacol Ther 16(2):185\u2013191. https:\/\/doi.org\/10.1177\/1074248410388807","journal-title":"J Cardiovasc Pharmacol Ther"},{"issue":"4","key":"1851_CR13","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1016\/j.jacc.2011.01.052","volume":"58","author":"JM Testani","year":"2011","unstructured":"Testani JM, Cappola TP, Brensinger CM, Shannon RP, Kimmel SE (2011) Interaction between loop diuretic-associated mortality and blood urea nitrogen concentration in chronic heart failure. J Am Coll Cardiol 58(4):375\u2013382. https:\/\/doi.org\/10.1016\/j.jacc.2011.01.052","journal-title":"J Am Coll Cardiol"},{"issue":"7","key":"1851_CR14","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1111\/ijcp.12144","volume":"67","author":"FL Dini","year":"2013","unstructured":"Dini FL, Ghio S, Klersy C, Rossi A, Simioniuc A, Scelsi L, Genta FT, Cicoira M, Tavazzi L, Temporelli PL (2013) Effects on survival of loop diuretic dosing in ambulatory patients with chronic heart failure using a propensity score analysis. Int J Clin Pract 67(7):656\u2013664. https:\/\/doi.org\/10.1111\/ijcp.12144","journal-title":"Int J Clin Pract"},{"issue":"12","key":"1851_CR15","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1136\/heartjnl-2013-305294","volume":"100","author":"RM Cubbon","year":"2014","unstructured":"Cubbon RM, Woolston A, Adams B, Gale CP, Gilthorpe MS, Baxter PD, Kearney LC, Mercer B, Rajwani A, Batin PD, Kahn M, Sapsford RJ, Witte KK, Kearney MT (2014) Prospective development and validation of a model to predict heart failure hospitalisation. Heart 100(12):923\u2013929. https:\/\/doi.org\/10.1136\/heartjnl-2013-305294","journal-title":"Heart"},{"issue":"3","key":"1851_CR16","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1002\/ejhf.462","volume":"18","author":"K Damman","year":"2016","unstructured":"Damman K, Kjekshus J, Wikstrand J, Cleland JG, Komajda M, Wedel H, Waagstein F, McMurray JJ (2016) Loop diuretics, renal function and clinical outcome in patients with heart failure and reduced ejection fraction. Eur J Heart Fail 18(3):328\u2013336. https:\/\/doi.org\/10.1002\/ejhf.462","journal-title":"Eur J Heart Fail"},{"issue":"12","key":"1851_CR17","doi-asserted-by":"publisher","first-page":"1431","DOI":"10.1093\/eurheartj\/ehi890","volume":"27","author":"A Ahmed","year":"2006","unstructured":"Ahmed A, Husain A, Love TE, Gambassi G, Dell\u2019Italia LJ, Francis GS, Gheorghiade M, Allman RM, Meleth S, Bourge RC (2006) Heart failure, chronic diuretic use, and increase in mortality and hospitalization: an observational study using propensity score methods. Eur Heart J 27(12):1431\u20131439. https:\/\/doi.org\/10.1093\/eurheartj\/ehi890","journal-title":"Eur Heart J"},{"issue":"1","key":"1851_CR18","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa1009492","volume":"364","author":"F Zannad","year":"2010","unstructured":"Zannad F, McMurray JJV, Krum H, van Veldhuisen DJ, Swedberg K, Shi H, Vincent J, Pocock SJ, Pitt B (2010) Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med 364(1):11\u201321. https:\/\/doi.org\/10.1056\/NEJMoa1009492","journal-title":"N Engl J Med"},{"issue":"6","key":"1851_CR19","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1093\/eurjhf\/hfq049","volume":"12","author":"F Zannad","year":"2010","unstructured":"Zannad F, McMurray JJ, Drexler H, Krum H, van Veldhuisen DJ, Swedberg K, Shi H, Vincent J, Pitt B (2010) Rationale and design of the eplerenone in mild patients hospitalization and survival study in heart failure (EMPHASIS-HF). Eur J Heart Fail 12(6):617\u2013622. https:\/\/doi.org\/10.1093\/eurjhf\/hfq049","journal-title":"Eur J Heart Fail"},{"issue":"3","key":"1851_CR20","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1002\/ejhf.235","volume":"17","author":"AD DeVore","year":"2015","unstructured":"DeVore AD, Hasselblad V, Mentz RJ, O\u2019Connor CM, Armstrong PW, McMurray JJ, Ezekowitz JA, Tang WH, Starling RC, Voors AA, Califf RM, Hernandez AF (2015) Loop diuretic dose adjustments after a hospitalization for heart failure: insights from ASCEND-HF. Eur J Heart Fail 17(3):340\u2013346. https:\/\/doi.org\/10.1002\/ejhf.235","journal-title":"Eur J Heart Fail"},{"issue":"5","key":"1851_CR21","doi-asserted-by":"publisher","first-page":"e006597","DOI":"10.1161\/circheartfailure.119.006597","volume":"13","author":"JP Ferreira","year":"2020","unstructured":"Ferreira JP, Eschalier R, Duarte K, Damman K, Gustafsson F, Schou M, Girerd N, Fay R, Tala S, Pitt B, Zannad F, Rossignol P (2020) Reduced diuretic dose in patients treated with eplerenone: data from the EPHESUS trial. Circ Heart Fail 13(5):e006597. https:\/\/doi.org\/10.1161\/circheartfailure.119.006597","journal-title":"Circ Heart Fail"},{"issue":"3","key":"1851_CR22","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1016\/j.jacc.2019.11.003","volume":"75","author":"M Vaduganathan","year":"2020","unstructured":"Vaduganathan M, Claggett BL, Desai AS, Anker SD, Perrone SV, Janssens S, Milicic D, Arango JL, Packer M, Shi VC, Lefkowitz MP, McMurray JJV, Solomon SD (2020) Prior heart failure hospitalization, clinical outcomes, and response to sacubitril\/valsartan compared with valsartan in HFpEF. J Am Coll Cardiol 75(3):245\u2013254. https:\/\/doi.org\/10.1016\/j.jacc.2019.11.003","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"1851_CR23","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1161\/circulationaha.114.013255","volume":"131","author":"MA Pfeffer","year":"2015","unstructured":"Pfeffer MA, Claggett B, Assmann SF, Boineau R, Anand IS, Clausell N, Desai AS, Diaz R, Fleg JL, Gordeev I, Heitner JF, Lewis EF, O\u2019Meara E, Rouleau JL, Probstfield JL, Shaburishvili T, Shah SJ, Solomon SD, Sweitzer NK, McKinlay SM, Pitt B (2015) Regional variation in patients and outcomes in the treatment of preserved cardiac function heart failure with an aldosterone antagonist (TOPCAT) trial. Circulation 131(1):34\u201342. https:\/\/doi.org\/10.1161\/circulationaha.114.013255","journal-title":"Circulation"},{"issue":"34","key":"1851_CR24","doi-asserted-by":"publisher","first-page":"2310","DOI":"10.1093\/eurheartj\/ehv273","volume":"36","author":"N Girerd","year":"2015","unstructured":"Girerd N, Collier T, Pocock S, Krum H, McMurray JJ, Swedberg K, Van Veldhuisen DJ, Vincent J, Pitt B, Zannad F (2015) Clinical benefits of eplerenone in patients with systolic heart failure and mild symptoms when initiated shortly after hospital discharge: analysis from the EMPHASIS-HF trial. Eur Heart J 36(34):2310\u20132317. https:\/\/doi.org\/10.1093\/eurheartj\/ehv273","journal-title":"Eur Heart J"},{"issue":"1","key":"1851_CR25","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1093\/ehjcvp\/pvx020","volume":"4","author":"CJ Kapelios","year":"2018","unstructured":"Kapelios CJ, Malliaras K, Kaldara E, Vakrou S, Nanas JN (2018) Loop diuretics for chronic heart failure: a foe in disguise of a friend? Eur Heart J Cardiovasc Pharmacother 4(1):54\u201363. https:\/\/doi.org\/10.1093\/ehjcvp\/pvx020","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"issue":"44","key":"1851_CR26","doi-asserted-by":"publisher","first-page":"3605","DOI":"10.1093\/eurheartj\/ehz554","volume":"40","author":"LE Rohde","year":"2019","unstructured":"Rohde LE, Rover MM, Figueiredo Neto JA, Danzmann LC, Bertoldi EG, Sim\u00f5es MV, Silvestre OM, Ribeiro ALP, Moura LZ, Beck-da-Silva L, Prado D, Sant\u2019Anna RT, Bridi LH, Zimerman A, Raupp da Rosa P, Biolo A (2019) Short-term diuretic withdrawal in stable outpatients with mild heart failure and no fluid retention receiving optimal therapy: a double-blind, multicentre, randomized trial. Eur Heart J 40(44):3605\u20133612. https:\/\/doi.org\/10.1093\/eurheartj\/ehz554","journal-title":"Eur Heart J"},{"issue":"5","key":"1851_CR27","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1016\/j.cardfail.2008.01.015","volume":"14","author":"LM Mielniczuk","year":"2008","unstructured":"Mielniczuk LM, Tsang SW, Desai AS, Nohria A, Lewis EF, Fang JC, Baughman KL, Stevenson LW, Givertz MM (2008) The association between high-dose diuretics and clinical stability in ambulatory chronic heart failure patients. J Card Fail 14(5):388\u2013393. https:\/\/doi.org\/10.1016\/j.cardfail.2008.01.015","journal-title":"J Card Fail"},{"issue":"6","key":"1851_CR28","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1007\/s10557-016-6697-7","volume":"30","author":"P Pellicori","year":"2016","unstructured":"Pellicori P, Cleland JGF, Zhang J, Kallvikbacka-Bennett A, Urbinati A, Shah P, Kazmi S, Clark AL (2016) Cardiac dysfunction, congestion and loop diuretics: their relationship to prognosis in heart failure. Cardiovasc Drugs Ther 30(6):599\u2013609. https:\/\/doi.org\/10.1007\/s10557-016-6697-7","journal-title":"Cardiovasc Drugs Ther"},{"issue":"7","key":"1851_CR29","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1016\/j.jacc.2008.10.040","volume":"53","author":"JGF Cleland","year":"2009","unstructured":"Cleland JGF, Tavazzi L, Daubert JC, Tageldien A, Freemantle N (2009) Cardiac resynchronization therapy: are modern myths preventing appropriate use? J Am Coll Cardiol 53(7):608\u2013611. https:\/\/doi.org\/10.1016\/j.jacc.2008.10.040","journal-title":"J Am Coll Cardiol"},{"issue":"3","key":"1851_CR30","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1002\/ejhf.1402","volume":"21","author":"O Vardeny","year":"2019","unstructured":"Vardeny O, Claggett B, Kachadourian J, Desai AS, Packer M, Rouleau J, Zile MR, Swedberg K, Lefkowitz M, Shi V, McMurray JJV, Solomon SD (2019) Reduced loop diuretic use in patients taking sacubitril\/valsartan compared with enalapril: the PARADIGM-HF trial. Eur J Heart Fail 21(3):337\u2013341. https:\/\/doi.org\/10.1002\/ejhf.1402","journal-title":"Eur J Heart Fail"}],"container-title":["Clinical Research in Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00392-021-01851-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00392-021-01851-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00392-021-01851-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,28]],"date-time":"2021-07-28T12:08:52Z","timestamp":1627474132000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00392-021-01851-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,6]]},"references-count":30,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2021,8]]}},"alternative-id":["1851"],"URL":"https:\/\/doi.org\/10.1007\/s00392-021-01851-w","relation":{},"ISSN":["1861-0684","1861-0692"],"issn-type":[{"value":"1861-0684","type":"print"},{"value":"1861-0692","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,5,6]]},"assertion":[{"value":"10 November 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 March 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 May 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Dr. Girerd received board fees from Novartis and honoraria from Servier. Dr. Rossignol received personal fees (consulting) from Novartis, Relypsa, AstraZeneca, Gr\u00fcnenthal, Stealth Peptides, Fresenius, Vifor Fresenius Medical Care Renal Pharma, Vifor, and CTMA; lecture fees from Bayer and CVRx; and is cofounder of CardioRenal. Dr Zannad received steering committte or advisory board fees from Amgen, AstraZeneca, Bayer, Boehringer, Boston Scientific, Cardior, CVRx, Janssen, Livanova, Merck, Mundipharma, Novartis, NovoNordisk and Vifor Fresenius. Dr Pitt received personal fees from Bayer, KDP pharmaceuticals, Astra Zeneca, Sanofi, Relypsa\/Vifor, scPharmaceuticals, stealth peptides, tricida, personal fees from G3 pharmaceuticals. Dr McMurray received fees for his consulting or trial committee work with Abbvie, Amgen, AstraZeneca\/Medimmune, Bayer, Bristol Myers Squibb, DalCor, GlaxoSmithKline, Merck, Novartis, Resverlogix, Sanofi-Aventis and Stealth Therapeutics. Dr Swedberg received personal fees from Novartis, AstraZeneca, Pfizer, and Novartis. Dr. Van Veldhuisen received board membership fees or travel expenses from Novartis, Corvia Medical, ARCA Biopharma and Johnson and Johnson. All other authors have no conflicts of interest to declare.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}